REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2018

Dec 14, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2018-12-12

Reporting Person: Landry Robert E (SVP Finance & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-12-12	Common Stock	A	12500	$0.0	Acquired	17348	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-12	Non-Qualified Stock Option (right to buy)	$381.4	A	20000	Acquired	2028-12-12	Common Stock (20000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	109	Indirect

Footnotes

F1: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on December 12, 2023.

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.